NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
Clinical Trials
41 trialsNCT05229601 2025-10-22
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Terminated
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT04502082 2025-09-08
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT04989387 2025-09-02
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
NCT05757492 2025-05-01
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Terminated
NCT05909995 2025-02-18
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT04244552 2023-12-29
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
Phase 1 Terminated
NCT04187872 2023-12-27
TORCH
University of Florida
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT02536183 2023-08-29
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Children's National Research Institute
Phase 1 Terminated
NCT04635527 2023-03-16
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT05093608 2022-10-17
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT03998033 2022-08-23
ET-109
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT02304289 2021-10-27
DESPARTH
University Hospital, Ghent
Phase 1 Terminated
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT03203304 2021-06-10
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
University of Chicago
Phase 1 Terminated
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT03511222 2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT03382886 2019-12-12
NUANCE
University of Utah
Phase 1 Terminated
NCT03349255 2019-07-01
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Aeon Therapeutics (Shanghai) Co., Ltd.
Phase 1 Terminated
NCT03145909 2018-11-29
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
AbbVie
Phase 1 Terminated
NCT00623077 2017-12-05
MT2004-30: Tomotherapy for Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01668017 2017-08-23
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT01829971 2016-09-27
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
Phase 1 Terminated
NCT00669136 2015-12-03
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
University of Pittsburgh
Phase 1 Terminated
NCT01521780 2015-11-02
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01348503 2015-08-31
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Indiana University
Phase 1 Terminated
NCT00955097 2013-10-21
Definity®
University of Louisville
Phase 1 Terminated
NCT00828594 2013-04-11
Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 1 Terminated
NCT00003147 2013-02-05
Gene Therapy in Treating Patients With Cancer of The Liver
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00426829 2012-08-01
Proton Therapy and Bevacizumab for Primary Liver Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00562666 2012-06-22
ICAR
Rennes University Hospital
Phase 1 Terminated
NCT00767468 2012-05-23
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00873002 2012-03-20
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Terminated